Azithromycin Dihydrate (Ophthalmic) interactions
Checked as Azithromycin in this data source.
Full monograph for Azithromycin Dihydrate (Ophthalmic)Check it against another medicine
Medicines
542 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloride | Major | Metabolism · Synergy | Amiodarone can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide… | 10 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Synergy | Artemether-lumefantrine may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…2 documented mechanisms | 16 sources — open the full entry |
| Betrixaban | Major | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the… | 11 sources — open the full entry |
| Cabozantinib | Major | Synergy | Cabozantinib can cause prolongation of the QT interval. | 7 sources — open the full entry |
| Ceritinib | Major | Synergy | Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Chloroquine Phosphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clozapine | Major | Synergy | Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation… | 13 sources — open the full entry |
| Colchicine | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Crizotinib | Major | Synergy | Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Efavirenz | Major | Metabolism | Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming… | 6 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Hydroxychloroquine Sulphate | Major | Synergy | Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong… | 22 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Ivabradine | Major | Synergy | Due to its bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased when ivabradine is used with drugs that prolong… | 10 sources — open the full entry |
| Ivosidenib | Major | Synergy | Ivosidenib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive… | 6 sources — open the full entry |
| Lefamulin Acetate | Major | Synergy | Lefamulin may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Loteprednol Etabonate + Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Mifepristone | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy | Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Moxifloxacin HydrochlorideInjectionOphthalmicTablet | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Synergy · Unknown | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 28 sources — open the full entry |
| Moxifloxacin Hydrochloride + Xanthan Gum | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Nilotinib | Major | Synergy | Nilotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval… | 9 sources — open the full entry |
| Osimertinib | Major | Synergy | Osimertinib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 5 sources — open the full entry |
| Pazopanib Hydrochloride | Major | Absorption | Coadministration with potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) may significantly increase the plasma… | 6 sources — open the full entry |
| Relugolix | Major | Absorption · Synergy | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 5 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption · Antagonism · Synergy | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…2 documented mechanisms | 43 sources — open the full entry |
| Ribociclib | Major | Synergy | Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 16 sources — open the full entry |
| Selpercatinib | Major | Synergy | Selpercatinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT… | 6 sources — open the full entry |
| Sotalol Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Sparfloxacin | Major | Synergy | Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT… | 21 sources — open the full entry |
| Ziprasidone | Major | Synergy | Ziprasidone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 10 sources — open the full entry |
| Abiraterone Acetate | Moderate | Synergy | Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 8 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that… | 30 sources — open the full entry |
| Adenosine | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Afatinib Dimaleate | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Synergy | Alfuzosin may cause modest prolongation of the QTc interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in… | 7 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids may reduce peak serum concentrations (Cmax) of oral azithromycin, but…2 documented mechanisms | 1 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Absorption | INTERVAL: The concomitant administration of aluminum or magnesium-containing antacids may reduce peak serum concentrations (Cmax) of oral azithromycin, but…2 documented mechanisms | 1 sources — open the full entry |
| Aminophylline | Moderate | Metabolism | Coadministration with certain macrolide antibiotics may increase the serum concentrations of theophylline, which may result in toxicity. The proposed mechanism… | 32 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular… | 24 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy | Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular… | 24 sources — open the full entry |
Conditions
Conditions in which Azithromycin Dihydrate (Ophthalmic) needs care, as documented in this source.
Colitis
MajorClostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.
31 sources
- "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
- "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
- "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
- "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
- "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
- "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
- "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
- "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
Show all 31 sourcesShow fewer sources
- "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
- "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
- "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
- "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
- "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
- "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
- "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
- "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
- "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
- "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
- "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
- "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
- "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
- "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
- "Product Information. Zemdri (plazomicin)." Achaogen (2018):
- "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
- "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
- "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
- "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
- "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
- "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
- "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
- "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):
Liver Diseases
MajorAzithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. Azithromycin is primarily eliminated by biliary excretion; however, the pharmacokinetics of azithromycin have not been established in patients with liver dysfunction. Therapy with azithromycin should be administered cautiously in patients with liver and/or biliary disease. Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, with some fatal cases. Treatment should be discontinued immediately if signs/symptoms of hepatitis occur.
2 sources
- "Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2022):
- "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
Long QT Syndrome
ModerateProlonged cardiac repolarization and QT interval have been reported in patients receiving treatment with azithromycin. Providers should consider the risk of QT prolongation, which can be fatal, when weighing the risks and benefits of azithromycin for at-risk patients including: patients with known prolongation of the QT interval, history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure; patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.
2 sources
- "Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2022):
- "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
Myasthenia Gravis
ModerateThe use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome. Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.
4 sources
- "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
- "Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2022):
- "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
- "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
Therapeutic duplication
Drug classes that overlap with Azithromycin Dihydrate (Ophthalmic), so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Prevpac
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Amoxicillin/clarithromycin/omeprazole
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Voquezna triple pak
macrolide-type antibiotics
The recommended maximum number of medicines in the 'macrolide-type antibiotics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'macrolide-type antibiotics' category.
Example product in the source data (US market): Pediazole